Kenvue's Distribution Challenges Pose a Near-Term Threat, but Our Long-Term Outlook Is Favorable
Despite the large debt balance compared with its current level of cash, we expect healthy cash generation from Kenvue to meet all of its near-term financial obligations. Only $1.5 billion of debt is ...
Sokolove Law6d
$8 Billion J&J Talc Bankruptcy Settlement Challenged by U.S. Health Agencies
Government agencies have challenged J&J's bankruptcy proposal, which includes $8 Billion for around 60,000 asbestos ovarian cancer lawsuits.
Fortune9d
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
An estimated 21 million American adults suffer from clinical depression. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...
Hindustan Times14d
Johnson & Johnson's Spravato nasal spray okayed as stand-alone treatment for depression
The United States Food and Drug Administration (FDA) has approved Spravato (esketamine), a nasal spray from Johnson & Johnson, as a stand-alone therapy for adults with major depressive disorder ...
Yahoo Finance16d
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...
mic16d
A Nasal Spray For Depression? FDA Gives Its Approval
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first standalone therapy for adults suffering from major depressive disorder ...
NBC New York17d
FDA approves Johnson & Johnson's nasal spray for depression as standalone treatment
The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.